Senescence medicine may need more than cell clearance.
A new Nature Aging paper reports something very interesting about CDK4/6 inhibition, abemaciclib and the inflammatory behaviour of senescent cells.
Senescent cells contribute to ageing and treatment-related dysfunction partly through the SASP: the senescence-associated secretory phenotype.
They have stopped dividing, but continue to send unhelpful pro-inflammatory signals to other cells.
The usual longevity approach tends to focus on senolytics: removing senescent cells. There is evidence that can be effective.
This paper asks a different question: Can we alter the pro-inflammatory signalling of senescent cells that are already present?
The authors describe an NF-κB-associated pro-inflammatory SASP programme, or NASP.
They show that short-term CDK4/6 inhibition with abemaciclib suppresses established NASP in pre-existing senescent cells, both in vitro and in vivo.
Mechanistically, the signal runs through a CDK4/6–RARα–NF-κB axis.
CDK4 and CDK6 interacted with NF-κB, while CDK4 also bound RARα.
Abemaciclib disrupted these interactions and reduced the inflammatory output of senescent cells.
In models of chemotherapy-induced senescence and ageing, this reduced senescence-associated inflammation and improved physical function.
Evidence that a senomorphic approach can work.
The available clinical lever is also interesting. Abemaciclib already exists as an oncology drug.
That does not make it a longevity drug.
The paper did not test abemaciclib as an anti-ageing treatment in humans.
It did not establish a safe protocol for healthy people.
It did not prove that CDK4/6 inhibitors should be used after chemotherapy to improve recovery.
It gives evidence that a senomorphic approach can be effective.
It gives another approach to sit alongside senolytic clearance.
Senescence biology is unlikely to be solved by one blunt strategy.
Some senescent cells may need clearing.
Some may need silencing.
Some may be doing useful repair work and should probably be left alone.
The next stage of senescence medicine is not just asking, “Can we remove senescent cells?”
It is asking which senescent-cell programmes are damaging, when they are damaging, and whether the right intervention is clearance, modulation or restraint.
That requires more than a senolytic shopping list.
It requires actual geroscience.
References
Wang et al.
Disruption of CDK4/6–RARα–NF-κB axis attenuates senescence-associated inflammation and improves function during aging and following chemotherapy.
Nature Aging, 2026.
PubMed record: PMID 42469443
Disruption of CDK4/6–RARα–NF-κB axis attenuates senescence-associated inflammation and improves function during aging and following chemotherapy.
Nature Aging research summary, 2026.
CDK4/6 regulators also regulate the inflammatory phenotype of senescent cells via retinoic acid signalling and NF-κB.
Muñoz-Espín D, Serrano M.
Cellular senescence: from physiology to pathology.
Nature Reviews Molecular Cell Biology, 2014.
Kirkland JL, Tchkonia T.
Senolytic drugs: from discovery to translation.
Journal of Internal Medicine, 2020.

